SCHEMBL4130341

SCHEMBL4130341

CCCCCCCC=COC=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.56
TRPV1 Q8NER1 2/20 0.56
TSHR P16473 2/20 0.50
ALDH1A1 P00352 1/20 0.47
TERT O14746 3/20 0.44
CYP1A2 P05177 2/20 0.44
MAPT P10636 2/20 0.44
CYP2C19 P33261 2/20 0.44
BLM P54132 2/20 0.44
HSD17B10 Q99714 2/20 0.44
FABP4 P15090 2/20 0.44
PTPN1 P18031 2/20 0.44
PPARG P37231 2/20 0.44
KMT2A Q03164 2/20 0.44
PPARD Q03181 2/20 0.44
PPARA Q07869 2/20 0.44
GMNN O75496 1/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10605584 1.00 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL4122077 1.00 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL8372060 1.00 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL2395653 1.00 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL3815755 1.00 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL3044334 1.00 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL6473139 1.00 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL6473135 1.00 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL3039634 1.00 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT
SCHEMBL6454894 1.00 FAAH (0.56) FAAHTRPV1TSHRALDH1A1TERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192153-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) 2009-07-30 US disclosed
US-20090118263-A1 Novel Adenine Compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-05-07 US disclosed
US-20090105212-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) 2009-04-23 US disclosed
US-20090099216-A1 NOVEL ADENINE COMPOUND ASTRAZENECA AKTIEBOLAG A CORPORATION OF SWEDEN (SE) 2009-04-16 US disclosed
US-20080269240-A1 Novel Adenine Compound Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) 2008-10-30 US disclosed
EP-1939198-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed
EP-1939199-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed
EP-1939202-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed
EP-1939200-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed
EP-1939201-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269240-A1 Novel Adenine Compound ADORA1, ADORA2A, ADORA3 FAAH 2347/4885TRPV1 1623/4885TSHR 2895/4885
US-20090118263-A1 Novel Adenine Compound ADORA1, ADORA2A, ADORA3 FAAH 2884/4885TRPV1 2036/4885TSHR 3415/4885
US-20090099216-A1 NOVEL ADENINE COMPOUND ADORA1, CXCR6, NR0B1 FAAH 3442/4885TRPV1 2509/4885TSHR 1269/4885
US-20090105212-A1 NOVEL ADENINE COMPOUND XDH, ADORA1, NUDT1 FAAH 3047/4885TRPV1 1774/4885TSHR 3563/4885
US-20090192153-A1 NOVEL ADENINE COMPOUND ADORA1, SLC28A1, ADORA2A FAAH 2659/4885TRPV1 921/4885TSHR 3960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.